Efficacy of dexfenfluramine in the treatment of alcohol dependence.
BACKGROUND
A substantial body of evidence supports a role for serotonin in modulating alcohol intake, which suggests that this neurotransmitter represents a promising target for pharmacotherapy development for alcohol use disorders. Dexfenfluramine. a serotonin releaser and reuptake inhibitor, decreases alcohol self-administration by rats. Its greater potency and several mechanisms of action suggest it should be more effective in treating alcohol dependence than drugs that only inhibit serotonin reuptake.


METHODS
We conducted an 11 week, randomized, double-blind trial that compared oral placebo and dexfenfluramine 7.5, 15, 22.5, and 30 mg bid in 136 alcohol-dependent patients. A brief behavioral intervention was offered concurrently.


RESULTS
The majority of subjects were male (72%), and the age of the group was 44 +/- 1 years (mean +/- SD). Both placebo- and drug-treated groups significantly reduced alcohol consumption compared with baseline (a 55% decrease in mean drinks per day; p < 0.01), but there were no significant differences between drug and placebo groups or dose effects for most outcome measures.


CONCLUSIONS
Our results with dexfenfluramine are further evidence that serotonergic medications on their own do not significantly reduce alcohol consumption in alcohol-dependent individuals. Combination pharmacotherapy with agents that act on different receptors or neurotransmitter systems (e.g., naltrexone plus dexfenfluramine) may be one way to enhance serotonergic effects on drinking behavior and should be considered in future medication development clinical trials.
Romach
M K
MK
Psychopharmacology and Dependence Research Unit, Centre for Research in Women's Health, Sunnybrook, Toronto, Ontario. myroslava.romach@utoronto.ca
Sellers
E M
EM
Kaplan
H L
HL
Somer
G R
GR
Gomez-Mancilla
B
B
D000328:Adult; D000368:Aged; D000428:Alcohol Drinking; D000437:Alcoholism / Q000188:drug therapy*; D020372:Dexfenfluramine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D010919:Placebos; D012727:Sex Characteristics
D010919:Placebos; D020372:Dexfenfluramine